Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy

Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15

Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...

Combined IL-15/IL-15R Immunotherapy Maximizes IL-15 Activity In Vivo

IL-2: the first effective immunotherapy for human cancer.

The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-c...

IL-21 in cancer immunotherapy

Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects.

whole tumor cell vaccine adjuvants: comparing il-12 to il-2 and il-15

cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. cancer vaccines induce pe...